Rani Therapeutics Holdings Inc（RANI）の財務RANIRani Therapeutics Holdings Inc

Evaluating the bottom line, Rani Therapeutics Holdings Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -516.86%, while the net margin is -493.03%. These profitability ratios, combined with a Return on Equity (ROE) of -179.10%, provide a clear picture of how effectively RANI converts its operational activities into shareholder value.

In the context of the broader market, RANI competes directly with industry leaders such as ANIX and QUCY. With a market capitalization of $117.09M, it holds a significant position in the sector. When comparing efficiency, RANI's gross margin of 100.00% stands against ANIX's N/A and QUCY's 66.12%. Such benchmarking helps identify whether Rani Therapeutics Holdings Inc is trading at a premium or discount relative to its financial performance.

Rani Therapeutics has shown a significant increase in contract revenue, achieving $1.7 million in Q2 2026, compared to zero a year ago, reflecting progress in commercialization efforts. The gross margin remains strong at 100% for recent quarters, indicating effective cost management in its operations.